$25.77
1.90%
Nasdaq, Sep 25, 12:19 pm EDT. Market open.

Amphastar Pharmaceuticals Inc Target price 2026 - Analyst rating & recommendation

Amphastar Pharmaceuticals Inc Classifications & Recommendation

Hold
67%
Sell
33%

Amphastar Pharmaceuticals Inc Price Target

Target Price $21.42
Price $26.27
Deviation
Number of Estimates 8
8 Analysts have issued a price target Amphastar Pharmaceuticals Inc 2027 . The average Amphastar Pharmaceuticals Inc target price is $21.42. This is lower than the current stock price. The highest price target is , the lowest is .
A rating was issued by 12 analysts: 0 Analysts recommend Amphastar Pharmaceuticals Inc to buy, 8 to hold and 4 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Amphastar Pharmaceuticals Inc stock has an average upside potential 2027 of . Most analysts recommend the Amphastar Pharmaceuticals Inc stock at Hold.

Sales and Margin forecast 2026, 2027 to 2031

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Million $ 719.89 764.39
1.65% 6.18%
EBITDA Margin 21.53% 28.22%
27.67% 31.06%
Net Margin 13.63% 16.84%
37.48% 23.59%

9 Analysts have issued a sales forecast Amphastar Pharmaceuticals Inc 2026 . The average Amphastar Pharmaceuticals Inc sales estimate is

$764m
unlock
. This is
4.71% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$804m 10.18%
unlock
, the lowest is
$697m 4.57%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $720m 1.65%
2026
$764m 6.18%
unlock
2027
$801m 4.84%
unlock
2028
$821m 2.49%
unlock
2029
$853m 3.83%
unlock
2030
$861m 0.96%
unlock
2031
$868m 0.83%
unlock

7 Analysts have issued an Amphastar Pharmaceuticals Inc EBITDA forecast 2026. The average Amphastar Pharmaceuticals Inc EBITDA estimate is

$216m
unlock
. This is
66.69% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$237m 83.12%
unlock
, the lowest is
$178m 37.28%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $155m 28.87%
2026
$216m 39.17%
unlock
2027
$222m 3.12%
unlock
2028
$233m 4.52%
unlock

EBITDA Margin

2025 21.53% 27.67%
2026
28.22% 31.06%
unlock
2027
27.76% 1.63%
unlock
2028
28.31% 1.98%
unlock

9 Amphastar Pharmaceuticals Inc Analysts have issued a net profit forecast 2026. The average Amphastar Pharmaceuticals Inc net profit estimate is

$129m
unlock
. This is
63.91% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$145m 84.14%
unlock
, the lowest is
$108m 37.43%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $98.1m 38.51%
2026
$129m 31.26%
unlock
2027
$138m 7.18%
unlock
2028
$147m 6.52%
unlock
2029
$113m 23.27%
unlock
2030
$107m 5.38%
unlock
2031
$102m 4.07%
unlock

Net Margin

2025 13.63% 37.48%
2026
16.84% 23.59%
unlock
2027
17.22% 2.26%
unlock
2028
17.90% 3.95%
unlock
2029
13.23% 26.09%
unlock
2030
12.40% 6.27%
unlock
2031
11.79% 4.92%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2031

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ 2.03 3.03
33.66% 49.26%
P/E 8.68
EV/Sales 1.88

9 Analysts have issued a Amphastar Pharmaceuticals Inc forecast for earnings per share. The average Amphastar Pharmaceuticals Inc EPS is

$3.03
unlock
. This is
71.19% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$3.40 92.09%
unlock
, the lowest is
$2.54 43.50%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $2.03 33.66%
2026
$3.03 49.26%
unlock
2027
$3.24 6.93%
unlock
2028
$3.46 6.79%
unlock
2029
$2.65 23.41%
unlock
2030
$2.51 5.28%
unlock
2031
$2.41 3.98%
unlock

P/E ratio

Current 14.84 49.81%
2026
8.68 41.52%
unlock
2027
8.10 6.68%
unlock
2028
7.60 6.17%
unlock
2029
9.91 30.39%
unlock
2030
10.47 5.65%
unlock
2031
10.91 4.20%
unlock

Based on analysts' sales estimates for 2026, the Amphastar Pharmaceuticals Inc stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.97 14.35%
2026
1.88 4.41%
unlock
2027
1.80 4.61%
unlock
2028
1.75 2.43%
unlock
2029
1.69 3.69%
unlock
2030
1.67 0.95%
unlock
2031
1.66 0.82%
unlock

P/S ratio

Current 1.53 13.92%
2026
1.46 4.49%
unlock
2027
1.39 4.61%
unlock
2028
1.36 2.43%
unlock
2029
1.31 3.68%
unlock
2030
1.30 0.95%
unlock
2031
1.29 0.82%
unlock

Current Amphastar Pharmaceuticals Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Barclays
Locked
➜
Locked
Locked Aug 18 2026
Wells Fargo
Locked
➜
Locked
Locked Aug 07 2026
Piper Sandler
Locked
➜
Locked
Locked Aug 07 2026
B of A Securities
Locked
➜
Locked
Locked Jun 29 2026
Barclays
Locked
➜
Locked
Locked Jun 03 2026
Wells Fargo
Locked
➜
Locked
Locked May 14 2026
Piper Sandler
Locked
➜
Locked
Locked May 11 2026
Analyst Rating Date
Locked
Barclays:
Locked
➜
Locked
Aug 18 2026
Locked
Wells Fargo:
Locked
➜
Locked
Aug 07 2026
Locked
Piper Sandler:
Locked
➜
Locked
Aug 07 2026
Locked
B of A Securities:
Locked
➜
Locked
Jun 29 2026
Locked
Barclays:
Locked
➜
Locked
Jun 03 2026
Locked
Wells Fargo:
Locked
➜
Locked
May 14 2026
Locked
Piper Sandler:
Locked
➜
Locked
May 11 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today